{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T23:14:14Z","timestamp":1778886854631,"version":"3.51.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals Incorporated","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.heliyon.2024.e33439","type":"journal-article","created":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T12:26:08Z","timestamp":1719059168000},"page":"e33439","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cystic fibrosis patient characteristics and healthcare resource utilization in Finland using linked registries"],"prefix":"10.1016","volume":"10","author":[{"given":"Kirsi","family":"Malmivaara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mari","family":"P\u00f6lkki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8672-9465","authenticated-orcid":false,"given":"Tuire","family":"Prami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paavo","family":"Raittinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eija","family":"Heikkil\u00e4","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antti","family":"Aalto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5159-1256","authenticated-orcid":false,"given":"Teija","family":"Dunder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9264-9904","authenticated-orcid":false,"given":"Varpu","family":"Elenius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristina","family":"Sandstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa J.","family":"McGarry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.heliyon.2024.e33439_bib1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1164\/rccm.200505-840OE","article-title":"Cystic fibrosis since 1938","volume":"173","author":"Davis","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33439_bib2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir. Med."},{"issue":"16","key":"10.1016\/j.heliyon.2024.e33439_bib3","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1056\/NEJMc1502191","article-title":"Origins of cystic fibrosis lung disease","volume":"372","author":"Stoltz","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"10059","key":"10.1016\/j.heliyon.2024.e33439_bib4","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","article-title":"Cystic fibrosis","volume":"388","author":"Elborn","year":"2016","journal-title":"Lancet."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e33439_bib5","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.2337\/dc09-0586","article-title":"Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality","volume":"32","author":"Moran","year":"2009","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e33439_bib6","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jcf.2005.06.002","article-title":"Spectrum of mutations in CFTR in Finland: 18 years follow-up study and identification of two novel mutations","volume":"4","author":"Kinnunen","year":"2005","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.heliyon.2024.e33439_bib7","year":"2024"},{"key":"10.1016\/j.heliyon.2024.e33439_bib8","series-title":"Orkambi (lumacaftor\/ivacaftor) summary of product characteristics, Vertex Pharmaceuticals (Ireland) Limited","year":"2023"},{"key":"10.1016\/j.heliyon.2024.e33439_bib9","series-title":"Symkevi (tezacaftor\/ivacaftor) summary of product characteristics, Vertex Pharmaceuticals (Ireland) Limited","year":"2023"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e33439_bib12","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/BF00210603","article-title":"Cystic fibrosis in a low-incidence population: two major mutations in Finland","volume":"93","author":"Kere","year":"1994","journal-title":"Hum. Genet."},{"key":"10.1016\/j.heliyon.2024.e33439_bib13","series-title":"Databases for Pharmacoepidemiological Research","first-page":"91","article-title":"Pharmacoepidemiological research data sources in the Nordic countries\u2014administrative registers in Finland, Sweden, and Norway","author":"Prami","year":"2021"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e33439_bib15","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jcf.2008.03.007","article-title":"The prevalence of cystic fibrosis in the European Union","volume":"7","author":"Farrell","year":"2008","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.heliyon.2024.e33439_bib16","unstructured":"European Cystic Fibrosis Society. Report European Cystic Fibrosis Society Patient Registry: Annual Data Report 2019. Available from: ECFS Patient Registry. Accessed 17 May 2024. ."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e33439_bib17","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(15)00545-7","article-title":"Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study","volume":"4","author":"Davies","year":"2016","journal-title":"Lancet Respir. Med."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e33439_bib18","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S2213-2600(18)30460-0","article-title":"Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2\u20135 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study","volume":"7","author":"McNamara","year":"2019","journal-title":"Lancet Respir. Med."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e33439_bib19","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S2213-2600(18)30202-9","article-title":"Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study","volume":"6","author":"Rosenfeld","year":"2018","journal-title":"Lancet Respir. Med."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e33439_bib20","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.3390\/jcm10071527","article-title":"Real-world outcomes of ivacaftor treatment in people with cystic fibrosis: a systematic review","volume":"10","author":"Duckers","year":"2021","journal-title":"J. Clin. Med."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e33439_bib21","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3390\/ph14090928","article-title":"State of the art on approved cystic fibrosis transmembrane conductance regulator (CFTR) modulators and triple-combination therapy","volume":"14","author":"Meoli","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.heliyon.2024.e33439_bib23","unstructured":"Cystic Fibrosis Foundation. Report Cystic Fibrosis Foundation Patient Registry: annual data report 2019. Available from:: https:\/\/www.cff.org\/sites\/default\/files\/2021-10\/2019-Annual-Report.pdf. Accessed 17 May 2024."},{"key":"10.1016\/j.heliyon.2024.e33439_bib24","unstructured":"Cystic Fibrosis Trust. Report UK Cystic Fibrosis Registry: Annual Data Report 2019. AVailable from: 2019 Registry Annual Data report_Sep 2020.pdf (cysticfibrosis.org.uk). Accessed 17 May 2024."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e33439_bib25","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1055\/s-0039-1697975","article-title":"Acute pulmonary exacerbations in cystic fibrosis","volume":"40","author":"Goss","year":"2019","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"10.1016\/j.heliyon.2024.e33439_bib26","year":"2024"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e33439_bib27","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1080\/20479700.2020.1725717","article-title":"Hospital-at-home network in Finland","volume":"14","author":"Ohvanainen","year":"2020","journal-title":"Int. J. Healthc. Manag."},{"key":"10.1016\/j.heliyon.2024.e33439_bib28","unstructured":"Suomen CF-yhdistys. Finland Joins the European CF Registry [Internet]. Available from:: https:\/\/www.hengitysyhdistys.fi\/suomencf\/finland-joins-the-european-cf-registry\/. Accessed 17 May 2024."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e33439_bib29","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1002\/ppul.25535","article-title":"Healthcare resource utilization and costs among children with cystic fibrosis in the United States","volume":"56","author":"Thorat","year":"2021","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.heliyon.2024.e33439_bib30","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2147\/CEOR.S162021","article-title":"The burden of cystic fibrosis in the Medicaid population","volume":"10","author":"Hassan","year":"2018","journal-title":"Clinicoecon Outcomes Res"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024094702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024094702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T22:48:39Z","timestamp":1778885319000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024094702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":26,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2405844024094702"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e33439","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cystic fibrosis patient characteristics and healthcare resource utilization in Finland using linked registries","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e33439","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e33439"}}